Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $52,500.00 in Stock

by · The Cerbat Gem

Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Free Report) Director Rosty Raykov sold 10,000 shares of the business’s stock in a transaction on Friday, April 4th. The shares were sold at an average price of $5.25, for a total transaction of $52,500.00. Following the sale, the director now directly owns 61,156 shares of the company’s stock, valued at approximately $321,069. The trade was a 14.05 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Rosty Raykov also recently made the following trade(s):

  • On Wednesday, March 5th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.79, for a total value of $67,900.00.
  • On Wednesday, February 5th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.66, for a total value of $66,600.00.
  • On Monday, January 6th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.08, for a total value of $60,800.00.

Fennec Pharmaceuticals Trading Down 6.1 %

Shares of NASDAQ:FENC traded down $0.34 during midday trading on Friday, reaching $5.25. 172,838 shares of the company were exchanged, compared to its average volume of 110,022. The stock has a market cap of $144.84 million, a PE ratio of -52.49 and a beta of 0.32. The business’s fifty day moving average is $6.53 and its two-hundred day moving average is $5.72. Fennec Pharmaceuticals Inc has a one year low of $3.96 and a one year high of $11.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp lifted its position in shares of Fennec Pharmaceuticals by 2.2% in the third quarter. State Street Corp now owns 328,259 shares of the company’s stock worth $1,641,000 after buying an additional 7,053 shares in the last quarter. Barclays PLC increased its stake in Fennec Pharmaceuticals by 274.3% in the 3rd quarter. Barclays PLC now owns 31,319 shares of the company’s stock worth $157,000 after acquiring an additional 22,951 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Fennec Pharmaceuticals by 18.7% during the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock worth $74,000 after acquiring an additional 2,330 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Fennec Pharmaceuticals by 12.9% during the 4th quarter. Rhumbline Advisers now owns 34,299 shares of the company’s stock valued at $217,000 after acquiring an additional 3,911 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Fennec Pharmaceuticals by 10.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 61,146 shares of the company’s stock valued at $386,000 after purchasing an additional 5,694 shares in the last quarter. Institutional investors own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Tuesday, March 11th. Wedbush reaffirmed an “outperform” rating and issued a $13.00 price objective on shares of Fennec Pharmaceuticals in a research note on Monday, March 10th.

Check Out Our Latest Research Report on FENC

About Fennec Pharmaceuticals

(Get Free Report)

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Featured Stories